Interview Highlights:

• Is synthetic nicotine truly ‘purer’ than tobacco-derived nicotine? No conclusive scientific evidence supports this claim. Manufacturers must provide rigorous research to validate purity and safety benefits.

• R-Nicotine: An overlooked risk? The toxicological and long-term health effects of R-nicotine remain largely unknown. Regulators need more data before approving products containing high levels of R-nicotine.

• Regulation: Innovation or loophole? Synthetic nicotine should not be a way to bypass tobacco regulations. It should be subject to the same safety and quality standards as tobacco-derived nicotine.

• Scientific validation: Is a global standard needed? There is currently no universally accepted method to distinguish synthetic from natural nicotine. A standardized scientific framework is essential for market transparency and regulatory consistency.

• Market future: Short-term trend or long-term opportunity? The future of synthetic nicotine depends on scientific validation and regulatory developments. Companies must prepare for stricter oversight.

The Synthetic Nicotine Disruption: Market Shift and Regulatory Challenges

2Firsts: The nicotine market is at a turning point, with synthetic nicotine rapidly gaining ground while natural tobacco-derived nicotine remains the industry standard. What are the driving factors behind this shift, and how is Labstat helping to shape the conversation?

Dr. Pete Gibbons: As a global leader in tobacco and nicotine research, Labstat International has been at the forefront of investigating the composition of nicotine used in Next-Generation Products (NGPs). Increasingly, manufacturers seek scientific validation to differentiate between tobacco-derived and synthetic nicotine, as regulators in various markets tighten their grip on the category.

2Firsts: In some regions, regulators have already taken action against synthetic nicotine. Could you share an example of such regulatory shifts and how companies are responding?

Dr. Pete Gibbons: A notable example is Costa Rica, where in 2024, the Ministry of Health implemented a ban on e-liquids containing synthetic nicotine. In response, producers and importers of Electronic Nicotine Delivery Systems (ENDS) and modern oral products (such as nicotine pouches) turned to Labstat for certification proving their nicotine was tobacco-derived. However, while there are scientific techniques to distinguish synthetic from tobacco-derived nicotine, no standardized global method has been universally accepted. Isotope analysis, for example, offers a potential solution, but it remains expensive and requires specialized equipment and expertise. Additionally, its applicability across all nicotine-containing product formulations is still being evaluated. Dr. Gibbons stresses that without a globally recognized standard, regulatory uncertainty will continue to create significant market challenges.

R-Nicotine: The Scientific Unknown in the Synthetic Nicotine Debate

2Firsts: There is growing debate over whether synthetic nicotine is truly identical to tobacco-derived nicotine in terms of chemistry, safety, and consumer experience. What are the key scientific distinctions between these two forms, and what implications do they have for the industry?

Dr. Pete Gibbons: Nicotine is a chiral molecule, meaning it exists in two mirror-image forms: S-nicotine and R-nicotine. Tobacco-derived nicotine is composed of over 99% S-nicotine, while early synthetic nicotine formulations resulted in a 50:50 racemic mixture of both enantiomers. Advances in chemical synthesis now allow the production of high-purity S-nicotine, making synthetic nicotine increasingly competitive with its natural counterpart.

2Firsts: What do we currently know about R-nicotine, and why is it an area of concern for scientists and regulators?

Dr. Pete Gibbons: One of the biggest unknowns in this space is R-nicotine. Research indicates it is a much weaker activator of nicotine receptors in the brain than S-nicotine, but there is still insufficient toxicological and pharmacological data to determine its long-term effects. The lack of a robust Toxicological Risk Assessment (TRA) framework for R-nicotine means regulators and manufacturers alike are working with limited information—a challenge that could influence future policy decisions. Dr. Gibbons warns that without rigorous studies on R-nicotine’s toxicity, metabolism, and behavioral effects, regulators will struggle to establish clear safety guidelines.

2Firsts: Some manufacturers claim synthetic nicotine has benefits like cleaner taste and fewer impurities. How much scientific backing exists for such claims?

Dr. Pete Gibbons: While synthetic nicotine’s costs are falling, its analytical differentiation from tobacco-derived nicotine remains challenging. Carbon isotope analysis is one potential approach, but its effectiveness varies depending on product formulations. Some companies claim synthetic nicotine offers a cleaner taste, fewer impurities, and no residual odor—but while preliminary research suggests possible differences in impurity profiles, Dr. Gibbons emphasizes that there is currently no conclusive peer-reviewed research demonstrating that synthetic nicotine provides a significant safety or quality advantage over tobacco-derived nicotine. He states that claims of superior purity must be substantiated by rigorous scientific studies before being accepted by regulators or the public.

With little published research on the long-term health implications of synthetic nicotine, regulators are treading cautiously. As the market expands, expect greater scrutiny from both scientific bodies and public health authorities.

Regulatory Uncertainty: The Battle Over Synthetic Nicotine Oversight

2Firsts: The regulatory landscape for synthetic nicotine is still in flux. How are governments responding to this emerging market, and what challenges do manufacturers face in securing long-term market access?

Dr. Pete Gibbons: The conversation around synthetic nicotine is heating up as policymakers weigh the battle between consumer protection and harm reduction. While tobacco-derived nicotine products are governed by well-established regulations, synthetic nicotine NGPs exist in a regulatory no-man’s land in many jurisdictions. Some countries regulate synthetic nicotine as a consumer product, while others are integrating it into tobacco control laws—but the lack of global regulatory alignment is creating uncertainty for businesses.

2Firsts: What kind of scientific validation will be required for synthetic nicotine products to gain wider regulatory approval?

Dr. Pete Gibbons: The key battleground? Scientific validation. Companies producing R-nicotine-containing products should be required to provide comprehensive toxicological and abuse liability studies, proving their safety and potential harm reduction benefits. Regulatory bodies should demand clear labeling that discloses whether a product contains synthetic or natural nicotine, preventing misleading marketing tactics. Dr. Gibbons underscores that companies that fail to provide transparent scientific evidence risk facing stricter regulations or market bans in the near future.

2Firsts: Some argue that synthetic nicotine is being used as a loophole to bypass tobacco regulations. What’s your perspective on this concern?

Dr. Pete Gibbons: Crucially, synthetic nicotine should not be used as a regulatory loophole to bypass tobacco product laws. Some regulators have already taken steps to close these gaps—for instance, the U.S. FDA amended its definition of a tobacco product to explicitly include synthetic nicotine under the same regulatory framework as tobacco-derived nicotine. This move ensures that synthetic nicotine products must meet the same compliance and safety requirements as traditional nicotine products. Dr. Gibbons asserts that regulators worldwide will likely follow suit, ensuring that synthetic nicotine is subject to the same rigorous oversight as tobacco-derived nicotine.

For companies navigating this evolving landscape, the message is clear: gear up for a regulatory fight and be transparent with the science. The future of nicotine will be shaped by data, regulation, and industry integrity—determining whether synthetic nicotine becomes a legitimate competitor or is reined in by stricter policies.

The Future of Nicotine: Balancing Innovation, Safety, and Regulation

The future of nicotine will be shaped by data, regulation, and industry integrity—determining whether synthetic nicotine becomes a legitimate competitor or is reined in by stricter policies.

About Labstat

The World’s Leading Nicotine Product Testing Laboratory

As part of Certified Group, Labstat is committed to delivering high-quality technical solutions our customers can feel confident in – on time, every time – so the world can trust in what it consumes. As one of the world’s largest independent testing laboratories, Labstat specializes in analytical chemistry, in vitro toxicology, microbiology, method development, and customized technical services for global clients in the tobacco, nicotine, cannabis, hemp, and natural health product categories.